Anti-platelet therapies improve endothelial function in atherosclerosis suggesting that platelets regulate vascular NO bioactivity in vivo. Herein, washed platelets consumed NO on activation in an aspirin-sensitive manner, and aspirin enhanced platelet NO responses in vitro. To examine whether in vivo aspirin can inhibit platelet NO consumption, a double-blind placebo-controlled study was conducted. After a 2 week NSAID-free period, healthy males were randomized and administered aspirin (75mg/day oral) or identical placebo for 14 days, then crossed over to the opposite arm.
Introduction
The free radical gas nitric oxide (NO) is a bioactive mediator formed in the vasculature that has important roles in regulating vascular tone in vivo. [1] [2] [3] [4] In vascular disease, impaired NO signaling through its accelerated removal is often observed. NO removal may occur through its reaction with free radicals formed by enzymes that are upregulated as part of the disease. Free radical pathways that are induced and can consume NO include NADPH oxidase, lipoxygenases (LOX), heme peroxidases and cyclooxygenases (COX). [5] [6] [7] [8] In particular, an involvement of platelet COX in regulating NO bioactivity is suggested by numerous clinical studies. For example, in hypercholesterolemia and hypertension, impaired acetylcholine-induced vasodilatation is restored by acute i.v. or oral low-dose aspirin. [9] [10] [11] [12] Also, antiplatelet GPIIbIIIa antagonists improve flowmediated dilatation of patients with coronary artery disease suggesting a direct role for platelets in modulating NO bioactivity in vivo. 13 Finally, we previously found that platelet COX-1 can consume NO in vitro. 6 Aspirin is routinely prescribed to patients with vascular disease as an inhibitor of COX-1.
Therefore, this study examined whether aspirin could block platelet COX-1-dependent NO consumption and enhance platelet NO responses in vitro. Additionally, the ability of clinicallyutilized doses of oral aspirin to inhibit platelet NO consumption were examined in a double-blind crossover study. Results show that in vitro or in vivo aspirin effectively inhibits NO consumption by platelets from healthy male subjects, and can partially restore cGMP levels following platelet activation. In a separate sub-study, NO consumption by platelets from hypercholesterolemic patients was faster and relatively less sensitive to in vivo aspirin, than NO consumption by platelets from corresponding controls. The data suggests that aspirin may improve NO bioactivity by inhibiting
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From platelet COX-1-dependent NO consumption, although this beneficial effect may be compromised in some patients with hypercholesterolemia.
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Methods
Isolation of washed platelets. Whole blood was collected from healthy volunteers free from nonsteroidal anti-inflammatory drugs (NSAID) for at least 14 days, into acid-citrate-dextrose (ACD; trisodium citrate, 2.5 g/100 ml, citric acid, 1.37 g/100 ml, glucose, 2 g/100 ml) (blood:ACD, 8.1:1.9 v/v) and centrifuging at 250 x g, 10 min, room temperature. The platelet-rich plasma was recentrifuged at 900 x g, 10 min and the pellet resuspended in Tyrode's buffer (134 mM NaCl, 12 mM NaHCO 3 , 2.9 mM KCl, 0.34 mM Na 2 HPO 4 , 1 mM MgCl 2 , 10 mM Hepes, 5 mM glucose, pH 7.4) containing ACD (1:9 v/v). The platelets were washed by centrifuging at 800 x g, 10 min then resuspended in Tyrode's buffer.
Measurement of NO consumption by washed platelets.
Anaerobic solutions of NO were prepared as described, and measured electrochemically using an NO sensor (AmiNO100, Harvard Apparatus). 6, 7 When NO loss was not linear, rates are given as first order rate constants (k obs )
calculated by determining the slope of ln [NO] versus time according to Equation 1.
Where NO loss on addition of arachidonate was linear, the slope of the initial rate of NO disappearance was determined. For all NO uptake rates and first order rate constants, data are the means ± SEM (n 3 determinations per donor, with n 3 donors per group). For platelet NO consumption, NO (3.8 µM) was added to 0.5 ml of Tyrode's buffer containing 1 mM CaCl 2 , and 2 x
For personal use only. In vitro treatment of washed platelets with aspirin. Washed platelets from healthy volunteers or hypercholesterolemic women were incubated with 1 mM aspirin for 30 min at room temperature, before being assayed for NO consumption as described above. For determination of cGMP, 5 x 10 8 platelets with/without aspirin pre-treatment (as above) were added to Tyrode's buffer, 5 mM CaCl 2 , 1 mM isobutyl methyl xanthine (IBMX), 1 mM L-nitroarginine-methyl-ester (L-NAME) and incubated with/without 1.9 µM NO, 40 µM arachidonate for 37º for 5 min. Following this, samples were taken in triplicate for determination of cGMP using radioimmunoassay. 6 Platelet aggregation in response to thrombin (0.4 U.ml -1 ) was determined using a PAP4 optical aggregometer (BioData Corp). Aspirin-treated or control platelets were activated with thrombin in Tyrode's buffer, 5 mM CaCl 2 , 10 sec before addition of 1.9 uM NO.
Recruitment of subjects for in vivo studies. All human studies were approved by Bro Taf Local
Research Ethics Committee (Study Number 01/4302). Normocholesterolemic male volunteers (NM, age 22-33, cholesterol < 5.9 mM) were recruited from workplace colleagues. Normocholesterolemic (NF, age 50-60, cholesterol < 5.9 mM) or hypercholesterolemic (HF, age 56-66, cholesterol > 6.4 mM) post-menopausal women were recruited by advertisement. Exclusion criteria were smoking (< 6 months prior to study), previous treatment with lipid-lowering medication, recent MI (< 3 months), hypertension (B.P. > 140/80 mmHg), diabetes, gastric bleeding, peptic ulcer disease and a known sensitivity to aspirin. All subjects gave written informed consent. (Fig. 1 B) . There was a range in control rates of arachidonate-stimulated NO consumption (ranging from 0.5 -1.8 nmol.min.2 x 10 8 platelets -1 ), reflecting donor variability (Fig 1C) . This data demonstrates that inhibition of COX-1 by aspirin in vitro prevents NO consumption by washed platelets.
Time course and dose-response of aspirin inhibition of NO consumption in washed platelets.
To characterize the sensitivity of platelets to aspirin inhibition of NO, time course and dose-response curves were constructed. Time course experiments showed that even 5 min is sufficient for almost complete inhibition of NO consumption by 1 mM aspirin (Fig 2 A) , while varying doses showed that aspirin concentrations as low as 0.1 mM inhibit effectively within 15 min at room temperature (Fig 2   B ).
Aspirin partially restores NO-dependent elevation of cGMP and enhances the inhibitory effects of NO on aggregation, following platelet activation. To determine whether aspirin could enhance platelet NO bioactivity, aggregation and cGMP responses were determined following addition of NO to activated platelets. Incubation with 1.9 µM NO caused a large increase in washed platelet cGMP, that was significantly attenuated by arachidonate (Fig 3 A) . If platelets were pretreated with aspirin, the ability of NO to elevate cGMP in the presence of arachidonate was significantly restored (Fig 3 A) . Aggregation of platelets to high dose thrombin (0.4 U.ml -1 ) was unaffected by aspirin (Fig 3 B,C) . However, the inhibitory effect of NO on aspirinized platelets was significantly greater than for controls (Fig 3 B,C) . Since NO or cGMP analogs can effectively block thrombin-stimulated arachidonate release by inhibiting PLA 2 , the order of addition in these experiments was reversed, with NO added 10 sec after thrombin. [15] [16] [17] These data indicate that the ability of NO to block platelet responses is enhanced by aspirin.
In vivo aspirin supplementation inhibits platelet NO consumption by washed platelets from healthy volunteers. At baseline, washed platelets from NM volunteers (n = 5, mean total chol. 4.74 mM) did not consume NO (Fig. 4 A) . On addition of 50 µM arachidonate, platelets consumed NO at rates of 1.31 ± 0.37 nmol.min -1 .2 x 10 8 platelets -1 . Following placebo, platelet NO consumption was unchanged from baseline, however aspirin (75 mg.day -1 ) supplementation for 14 days reduced arachidonate-stimulated NO consumption by 95 % (1.35 ± 0.47 versus 0.07 ± 0.02 nmol.min -1 .2 x 8 platelets -1 , for placebo or aspirin, respectively), indicating that in vivo inhibition of COX-1 by aspirin effectively prevents platelet NO consumption (Fig 4 A,B) . To characterize the onset of inhibition of NO consumption, and its recovery following aspirin withdrawl, healthy male volunteers (n = 3) were administered aspirin (75 mg.day -1 ) for 3 days and NO consumption measured daily, before, during and 3 days post aspirin withdrawl. Onset of inhibition was gradual, and essentially complete by day 3. Following aspirin withdrawl, NO consumption recovered over the following 3 days and was back to baseline by day 6 (Fig. 4 C) . These data indicate that inhibition of NO consumption by aspirin is transient and parallels inhibition of COX-1 in vivo 18 .
In vivo aspirin supplementation only partially inhibits platelet NO consumption by washed platelets from HF subjects. Resting washed platelets from a group of HF subjects (n = 6, mean total chol. 7.01 mM) did not consume NO ( Fig. 5 A partially inhibits platelet NO consumption in HF subjects (Fig 5 A,B) . Indeed, in 3 of the 6 subjects, rates of NO consumption following aspirin treatment were either unchanged or slightly increased over baseline (not shown). NO consumption was then determined in a group of NF subjects (n = 4, mean total chol 5. (Fig 6 D) . These data indicate that a higher dose of aspirin may be more effective at improving NO bioactivity in hypercholesterolemic females.
Expression of COX isoforms and MPO in platelets from NF or HF volunteers. To examine
whether the elevated NO consumption rates could be related to expression of COX isoforms in hypercholesterolemics, COX-1 and -2 expression was compared in HF or NF platelets. As expected, both groups expressed COX-1, and following actin-normalization, expression levels were found to be similar (Fig 7 A,B) . Analysis for COX-2 revealed some weak staining for this isoform that was similar in both HF and NF groups (Fig 7 A,C) . Expression of COX-2 in platelets is controversial and could indicate leukocyte contamination or cross-reactivity of the anti-COX-2 antibody with COX-1.
To exclude leukocyte contamination, western blots examined for expression of the leukocyte protein myeloperoxidase. As shown, we did not detect MPO in our patient samples, and additionally do not find leukocytes in our platelets when viewed by haemocytometer following isolation (Fig 7 D , data not shown).
Urinary thromboxane excretion after aspirin supplementation in the three groups. To examine the effect of in vivo aspirin on COX-1 activity in the study groups, urinary levels of 11-dehydro-TXB 2 were determined by GC/MS. In NM or NF subjects, placebo had no effect while aspirin supplementation reduced 11-dehydro-TXB 2 levels by 66 % or 57 % respectively, compared with baseline, whereas placebo had no effect (Fig. 8) . In contrast, 11-dehydro-TXB 2 excretion was approximately doubled in the HF group and was not reduced by aspirin, compared with baseline.
For
Discussion
In vitro, activated platelets consume NO via COX-1 peroxidase turnover, with 2 molecules of NO consumed per catalytic cycle. 6 Platelet NO consumption could regulate both platelet and vascular wall responses to endothelial NO. However, we suggest that regulation of platelet NO bioactivity in vivo may be a less likely consequence, since NO consumption occurs after agonist stimulation. In contrast, platelets are stimulated to aggregate and secrete at sites of vascular injury, a setting where vasodilation would not be beneficial. Therefore, a pathophysiological role for platelet NO consumption in promoting hemostasis at sites of platelet plug formation is proposed.
In vivo, antiplatelet GPIIbIIIa antagonists or i.v. or oral low-dose aspirin improve endothelial dysfunction in patients with cardiovascular disease. [9] [10] [11] [12] [13] Therefore it is likely that the behavior of circulating platelets will be a critical determinant of the level of bioactive NO in cardiovascular disease. Our current study extended to inhibition of COX-1 in vivo, and asked whether supplementation with aspirin, the universally-prescribed inhibitor of this pathway, could alter platelet NO consumption. Herein, in vivo aspirin administration inhibited platelet NO consumption ex vivo in NM subjects by 95% (Fig 4 A,B) . Inhibition showed a gradual onset over 3 days, and recovered during the 3 days following aspirin withdrawl (Fig 4 C) . This pattern is consistent with inhibition of COX-1 and its recovery in vivo as previously shown by measurement of urinary thromboxane metabolite excretion.
18
We note that there are technical issues that preclude the use of thrombin in studies where NO consumption rates are to be determined. In particular, NO suppresses thrombin-stimulated aggregation and arachidonate release, so thrombin is added before NO to ensure platelet activation occurs. This does not allow accurate determination of NO consumption, since a linear rate of NO decay is not detected by the electrode. 6 (Fig. 4B ) For this reason, we utilize arachidonate for
quantitative assays since activation of COX-1 is achievable following addition of NO and its peak detection by the electrode (Fig. 1 A(ii) ). Inhibition of thrombin-stimulated NO consumption by NO does not preclude its occurrence in vivo. Indeed, patients with vascular disease consistently show elevated thromboxane in vivo in tandem with impaired NO bioactivity that can be improved by aspirin, indicating that this phenomenon does occur in the vasculature. [9] [10] [11] [12] 19 Resting washed platelets did not consume NO in vitro, however circulating platelets are not resting in vivo. Detection of urinary thromboxane metabolites, and their elevated levels in patients with vascular disease indicates platelet COX-1 turnover.
19 Also, aspirin (including low dose oral)
improves NO bioactivity in patients with hypertension and vascular disease. were also effective ( Fig. 1, 2 A,B) . Also, aspirin pre-treatment partially restored NO-dependent cGMP synthesis that was inhibited by COX-1 turnover (Figs. 3 A) . It is not clear why cGMP synthesis was only partially restored, since NO consumption was fully blocked. One potential explanation is activation of phosphodiesterases (PDE) by NO, and indeed NO/cGMP is known to activate PDE5, the main enyzme responsible for cGMP hydrolysis in intact cells. 20 Although we included IBMX (inhibitor of PDEs) in our experiments, we cannot exclude incomplete inhibition of this pathway could have occurred.
Previously we showed that inhibition of platelet aggregation by NO can be prevented by activation of COX-1. Specifically, aggregation of platelets triggered via the thromboxane receptor
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From (TP) using U46619 is more sensitive to the inhibitory effects of NO than aggregation triggered by arachidonate. For both agonists, aggregation results from TP activation, however U46619 is not a substrate for COX-1 and does not stimulate NO consumption. 6 While exogenous arachidonate may not be a physiological substrate for platelet aggregation, thrombin also stimulated NO consumption and suppressed NO stimulation of cGMP generation in platelets via COX-1 turnover. 6 Furthermore, herein, the ability of NO to block aggregation of platelets in response to high dose thrombin, was significantly greater in aspirinized than control platelets (Fig 3 B,C) . Taken together, these data indicate that COX-1-dependent NO consumption provides a mechanism by which platelets could regulate NO bioactivity in vivo, and by which endothelial dysfunction could be improved by aspirin supplementation.
In a small sub-study, rates of NO consumption by platelets isolated from HF volunteers were almost twice those of healthy subjects indicating that the ability of platelets to remove NO in hypercholesterolemia may be increased (Figs. 5) . Elevated NO consumption in HF subjects could result from elevated expression and/or activity of COX isoforms in platelets. Indeed, patients with hypercholesterolemia have elevated urinary thromboxane metabolites, as shown herein and by others. 19 (Fig 8) However, platelet levels of both COX isoform proteins were unaltered in these subjects ( Fig. 7) , suggesting that COX-1 turnover is elevated in this group, rather than its expression.
Detection of COX-2 in our samples was perhaps unexpected, since its expression in platelets is controversial, however others have found this isoform in < 10% of circulating platelets from healthy subjects.
21-23
NO consumption by platelets from HF subjects was inhibited by in vivo aspirin only 39%, versus 76% for matched controls (Fig. 5) . In contrast, HF platelet NO consumption was inhibited 87% inhibited by aspirin in vitro (Fig. 6A-C ). This suggests a failure of low-dose aspirin to inhibit COX-1 in vivo in this group, and is supported by findings that elevated urinary 11-dehydro TXB 2 was also not suppressed at this dose (Fig 8) . However, on administration of a 2-fold higher dose of aspirin for 14 days, NO consumption was more effectively blocked, and approached in vitro levels of inhibition (Fig. 6 D) . This indicates that COX-1 is still sensitive to aspirin in these patients, but that its bioavailability may be decreased.
Aspirin resistance has been suggested as a new independent predictor of vascular effects, although its exact definition is not standardized. 24, 25 It may transiently increase following vascular surgery, and estimations of its prevalence vary from 75% to 5.5%, however studies vary widely in their platelet functional assays and agonist concentrations. [25] [26] [27] [28] [29] [30] Pharmacologically, aspirin resistance is defined as persistent production of thromboxane despite therapy. 31,32 Although our sample size is small, it suggests a higher prevalence of aspirin resistance in hypercholesterolemia. Several mechanisms of aspirin resistance have been proposed including (i) aspirin-insensitive COX-1, e.g.
with a mutation at or near serine 529, (ii) thromboxane generation mediated by platelet or vascular COX-2, and (iii) COX-1 expression in nucleated vascular cells. 21, 28 Our data showing that platelets resistant to low dose aspirin in vivo are fully sensitive in vitro rules out a COX-1 mutation, at least in this small group of subjects (Fig 6) . It is also unlikely that platelet COX-2 contributes to inability of aspirin to block NO consumption in our study, since (i) HF and NF subjects showed identical levels of platelet COX-2 protein herein and (ii) selective COX-2 inhibitors do not decrease systemic biosynthesis of thromboxane in vivo. 33 (Fig. 7) Our data showing that higher doses of aspirin are required to inhibit NO consumption suggests altered in vivo pharmacokinetics of the drug, e.g.
increased binding to plasma proteins, or rate of hydrolysis in the gut content, gut wall and liver. This could be investigated by determining bioavailability of systemic aspirin as has been previously done in healthy volunteers. 34 It should be noted that our sample size was small, due to difficulties in recruiting newly-diagnosed hypercholesterolemic subjects that had not been treated with medication for vascular disease. Notwithstanding this issue, significant effects of aspirin on NO consumption were observed in NM and NF groups. Additionally, several of our findings were consistent with previous observation of others: (i) we observed a doubling of thromboxane metabolites in hypercholesterolemics versus controls, that was significant, (ii) aspirin suppressed thromboxane excretion in healthy males to a degree that was identical to previously reported studies.
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The study focused on women since it was considerably more difficult to recruit newly diagnosed male patients who had never been prescribed aspirin or lipid lowering therapies, however there are reasons to suspect that our findings are more applicable to hypercholesterolemic females.
For example, it has been previously noted that aspirin non-responders tend to be women and/or older, and the Women's Health Study recently reported that aspirin is not cardioprotective against myocardial infarction in women, unlike men, but it does protect against ischemic stroke 26,29. In summary, this study shows that aspirin blocks platelet NO consumption in vitro and enhances (i) the inhibitory effects of NO on aggregation and (ii) cGMP generation. Also in vivo aspirin effectively inhibits NO consumption by platelets from healthy male volunteers. In contrast, NO consumption by platelets from a small group of HF subjects was higher and less sensitive to aspirin. The findings suggest a role for platelet COX-1 in modulating NO bioactivity in vivo.
However, the beneficial effects of anti-platelet therapy on NO bioactivity may be compromised in patients with hypercholesterolemia. Cumulative data on the effect of aspirin-treatment on arachidonate-stimulated platelet NO consumption rates (mean ± SEM, n = 3 separate donors, * p < 0.05, students unpaired t-test). Baseline NO consumption following a 14 day NSAID-free washout period of washed platelets was determined as described in methods, then subjects were randomized to receive either aspirin or 
